4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Food Allergy by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 129 ongoing clinical trials involving Food Allergy
Of the 129 trials,47 trials are in Phase III
Furthermore, 45 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Food Allergy by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Food Allergy, an Immunology condition. The largest number of ongoing clinical trials for Food Allergy is conducted in Asia-Pacific. North America and Europe are among some of the other prominent regions engaged in Food Allergy-related drug trials.

Murdoch Childrens Research Institute and Stanford University: The leading ongoing Food Allergy related clinical trial sponsor

Murdoch Childrens Research Institute and Stanford University are the top sponsors for Food Allergy-related ongoing clinical trials.

Sagamihara National Hospital, DBV Technologies SA, Aimmune Therapeutics Inc, Icahn School of Medicine at Mount Sinai, and Aichi Children's Health and Medical Centre are among other notable clinical trial sponsors involved in Food Allergy. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Food Allergy

Epinephrine (Twinject/Adrenaclick) and Peanut (Arachis hypogaea) (Palforzia) are among the key marketed drugs involving Food Allergy.

Epinephrine (Twinject/Adrenaclick) is a catecholamine. It functions via Alpha 1 Adrenergic Receptor (ADRA1) Agonist; Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2) Agonist mechanism of action. Epinephrine is formulated as injection, solution for intramuscular route of administration. Twinject is indicated in emergency treatment for acute allergic reactions (anaphylaxis) caused by food, drugs, latex, insect bites or stings and other allergens, besides anaphylaxis caused by physical exercise or idiopathic. Epinephrine was first approved in 2003 and is marketed in the US and Spain by Amneal Pharmaceuticals Inc and Shionogi Ireland Ltd.

Peanut (Arachis hypogaea) (Palforzia) Allergen is an immunotherapy agent. It functions via AR-101 which is an oral immunotherapy for peanut allergy. It lowers the risk of anaphylactic reactions by raising the threshold needed to cause an allergic reaction. It is formulated as powder in capsules for oral route of administration. Palforzia is indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut in patients aged 4 years and over. Peanut (Arachis hypogaea) (Palforzia) was first approved in 2020 and is marketed globally including the US, the UK, France and Germany by Aimmune Therapeutics Inc.